In part three of AHA’s five-part series on opioid stewardship, Marie Cleary-Fishman, AHA’s vice president of clinical quality, speaks with Holly Geyer, M.D., hospital internal medicine practitioner sub-specialized in addiction medicine at Mayo Clinic, about the roots of the opioid epidemic and the state and federal requirements — and institutional protocols — for developing solutions. LISTEN HERE.


View the whole series.

Headline
The Food and Drug Administration March 5 issued a request for information seeking public comments on potential new standards for in-home opioid disposal…
Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…